Reuters logo
5 个月前
BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent
2017年3月28日 / 下午4点37分 / 5 个月前

BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent

March 28 (Reuters) - Sanofi SA :

* Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis

* Dupixent is expected to be available to patients and providers in U.S. later this week

* Regeneron and Sanofi Genzyme, specialty care global business unit of Sanofi, will market Dupixent in United States Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below